AVDL / Avadel Pharmaceuticals: Real-World Data Supports Market Opportunity For Lumryz

Avadel's Q2 2023 earnings report shows promising growth and FDA endorsement of Lumryz for narcolepsy treatment. Lumryz has seen positive commercializa more_horizontal

Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Austin Murtagh - Stern Inves more_horizontal

Avadel Pharmaceuticals plc finally won approval of Lumryz™ (sodium oxybate), despite cutthroat opposition from Jazz Pharmaceuticals plc. Potential s more_horizontal

Avadel: Sleeping Soundly, Why We're Giving A 'Buy' Rating Ahead Of Lumryz Launch more_horizontal

Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q4 2022 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Austin Murtagh – Stern Inv more_horizontal

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming med more_horizontal

Avadel Pharmaceuticals' Lumryz has the potential to transform the narcolepsy treatment market. Avadel estimates that the total potential patient popul more_horizontal

Lumyrz overhang now removed with competitor ordered to delist patent from FDA's Orange Book. The treatment has potential to create a remedial breakthr more_horizontal